Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Approximately 1%–2% of children with Down syndrome (DS) develop acute myeloid leukemia (AML) prior to age 5 years. AML in DS children (ML-DS) is characterized by the pathognomonic mutation in the gene encoding the essential hematopoietic transcription factor GATA1, resulting in N-terminally truncate...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sonali P. Barwe, Ishnoor Sidhu, E. Anders Kolb, Anilkumar Gopalakrishnapillai
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2020-12-01
coleção:	Molecular Therapy: Methods & Clinical Development
Assuntos:	Down syndrome iPSC CRISPR/Cas9 leukemia GATA1s
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2329050120301923
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!